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Abstract
Background: Anaplastic thyroid carcinomas are associated with rapid tumor growth, 
short survival time and without any promising therapy to improve the poor progno-
sis. In this study, expression of immunoregulative receptor CD1d and lymphocyte 
infiltration in different thyroid tumors as well as in healthy tissue were analyzed in 
order to find new targets for an immunotherapeutic approach.
Methods: CD1d immunohistochemistry was performed in samples of 18 anaplastic, 
17 follicular, 27 papillary, and 4 medullary thyroid carcinomas as well as in 19 speci-
mens from normal thyroid tissue and additionally in 10 samples of sarcoma, seven 
malignant melanoma and three spindle‐cell lung carcinoma. Furthermore, thyroid 
samples were stained with antibodies against CD3, CD20, CD56, CD68, and LCA in 
order to analyze lymphocyte infiltration.
Results: For the first time CD1d receptor expression on normal thyroid tissue could 
be demonstrated. Moreover, anaplastic thyroid carcinomas showed significantly 
higher expression levels compared to other thyroid samples. Most astonishingly, 
CD1d expression disappeared from the cellular surface and was detected rather in 
the cytoplasm of anaplastic thyroid carcinoma cells. In addition, histologically simi-
lar tumors to anaplastic carcinoma like sarcoma and malignant melanoma revealed 
distinct CD1d staining patterns. Furthermore, infiltration of T cells, B cells, and mac-
rophages in anaplastic thyroid carcinomas was different when compared to normal 
thyroid tissue and all other thyroid carcinomas.
Conclusions: Anaplastic thyroid carcinomas show significantly higher expression of 
CD1d, a receptor for NKT cells, which are subject of several anticancer therapy stud-
ies. These results may offer a novel approach to explore immunotherapeutic treat-
ment options.
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1 |  INTRODUCTION
The incidence of malignant thyroid tumors has increased 
over the last few years.1 These tumors represent a very 
heterogeneous group of malignancies, with distinct differ-
ences in histology and likewise in clinical outcome.1,2 Most 
thyroid malignancies are described as follicular or papil-
lary thyroid carcinomas (FTC/PTC) but about 1.7% of the 
patients are diagnosed with anaplastic thyroid carcinoma 
(ATC).3 ATC is a rare, yet rapidly growing neoplasm of the 
thyroid gland with a poor prognosis.4 In contrast to FTC or 
PTC, which can be treated postoperatively by radioiodine 
therapy, ATCs are not sensitive to any further treatment and 
therefore have the worst prognosis with a median survival 
of only 5 months.3,5 However, immunotherapy as new ther-
apeutic approach has been introduced against a wide range 
of solid tumors recently. Oncologic trials have focused on 
developing immunomodulating therapies to restore the 
functional ability of different immune cells against neo-
plastic cells and showed promising results in several tumor 
types, such as lung cancer, melanoma, and colon cancer.6,7 
Regarding malignant thyroid tumors, recent advances ap-
proached several strategies for immunomodulation, such 
as inhibiting recruitment of tumor‐associated macrophages 
(TAM), blocking and inhibiting of several immune check-
points, as well as identification of tumor‐specific antigens.8
In this context, natural killer T (NKT) cells, which are con-
sidered to be regulators of an inflammatory immune response, 
also represent a promising target for antitumor therapy.9-11 
They are a subset of lymphocytes that co‐express NK cell 
markers and the T‐cell receptor.12 In humans, NKT cell popu-
lation expresses the Vα24 and Jα18 gene segments, which are 
preferentially associated with Vβ11.13,14 NKT cells are acti-
vated through a specific receptor called CD1d, which belongs 
to a group of CD1 molecules associated with β2‐microglob-
ulin, and is known to present lipids, including glucosylcer-
amides and glycosylphosphatidylinositol to NKT cells.15 It is 
already known that activation of CD1d leads to the production 
of interleukin (IL)‐4 and interferon (IFN)‐g and an increase in 
the cytolytic activity of NKT cells.16 However, expression of 
CD1d, a MHC class I‐related molecule, could just be shown on 
hematopoietic cells and on epithelial cells of the intestine.9,17,18
In this study, the expression of CD1d and lymphocyte in-
filtration in healthy thyroid tissue as well as in several thyroid 
carcinomas was analyzed in order to find new targets for an 
immunotherapy approach.
2 |  MATERIALS AND METHODS
2.1 | Tissue samples
FFPE tissue samples were collected from the archives of 
the Institute for Pathology, Regensburg. Tumor entity was 
confirmed before anonymization. Two tissue micro arrays 
(TMAs), containing a total of 18 samples of ATC, 17 sam-
ples of FTC (12 grossly invasive, 5 minimally invasive), 
27 samples of PTC, and 4 samples of medullary thyroid 
carcinoma (MTC), were created with subsequent histo-
morphological control of the tumor samples by a trained 
pathologist (FW) using conventional H&E staining. The 
TMAs also contained 19 samples of normal thyroid tissue, 
as well as 10 samples of sarcoma (SRC; two myofibroblas-
tic sarcomas, two dedifferentiated liposarcomas, and one 
fibrosarcoma, leimyosarcoma, biphasic synovial sarcoma, 
clear cell sarcoma, carcinosarcoma and sarcomatoid renal 
cell carcinoma, respectively), seven samples of malignant 
melanoma (MM), and three samples of spindle‐cell lung 
carcinoma (SLC).
2.2 | Immunohistochemistry
For standard immunohistochemistry, 5  µm thick paraffin 
sections were processed using routine diagnostic antibodies 
and immunostaining protocols (Ventana immunostainer) of 
the Institute for Pathology, Regensburg for staining of CD3, 
CD20, CD56, CD68 (KP1), and LCA (CD45). The number 
of positively stained cells (lymphocytes or monocytes) per 
high‐power field (HPF, 400x magnification) for each tis-
sue sample was recorded and used for further analysis. For 
CD1d immunohistochemistry, a mouse monoclonal anti-
body against human CD1d (LifeSpan BioSciences, code: 
LS‐B6766, clone: ms R3) was used in a dilution of 1:50. 
The dewaxed paraffin sections were subjected to heat‐in-
duced epitope retrieval for 5 minutes at 120°C in Tris‐EDTA 
buffer at pH 8.5. The antigen localization was carried out 
using polymer‐based detection systems and an automated 
system setting with diaminobenzidine as the final substrate. 
Immunohistochemistry was evaluated by an expert patholo-
gist (FW); for CD3, CD20, CD56, CD68, and LCA, the num-
ber of specifically positive cells per high‐power field (HPF, 
400×) were counted. For CD1d, in addition to the number 
of specifically positive cells per HPF, the immunostaining 
of tumor/normal thyroid cells was assessed by an expert 
pathologist (FW) and a trained pathologist (NVC) accord-
ing to relative intensity of cytoplasmic (c) and membranous 
(m) staining, that is c > m, c = m, or m > c; some samples 
showed a completely negative staining reaction, and only one 
sample had nuclear positivity (Figure 1). In case of differing 
results between the two observers, a mutual consensus was 
found and recorded.
2.3 | Microscopy
Stained sections were viewed with a Leica light micro-
scope (Leitz DMRBE; Leitz). Images were acquired using a 
MIRAX digital slide scanner (Zeiss).
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2.4 | In situ hybridization
mRNA detection of CD1d (Hs‐CD1D #496771, 
ACDBio) was performed using the RNAscope 2.5 HD 
RED Reagent Kit (#322350, ACDBio) on 3‐μm FFPE 
sections of tissue micro arrays (TMAs) according to the 
manufacturer's instructions. RNA quality was evalu-
ated for each sample with a probe specific to the house-
keeping gene ubiquitin (Hs‐UBC, #310041, ACDBio). 
Negative control background staining was evaluated 
using a probe specific to the bacterial DapB gene (DapB, 
#310043, ACDBio). Only samples with an average of >4 
dots per cell with the housekeeping gene probe staining 
and an average of <1 dot per 10 cells with the nega-
tive control staining were assayed with target probes. 
Analysis was performed by two independent research-
ers on a Leica light microscope (Leitz DMRBE; Leitz) 
using a 40× objective. The RNAscope signal is scored 
on the basis of number of dots per cell as recommended 
by the manufacture (ACDscore) and was applied as fol-
lows 0 = 0 dot/cell, 1 = 1‐3 dots/cell, 2 = 4‐9 dots/cell, 
3 = 10‐15 dots/cell, and 4 = >15 dots/cell with > 10% of 
dots in clusters).
2.5 | Statistical analysis
D'Agostino & Pearson normality test did not confirm a nor-
mal distribution of the data set. Therefore, results are shown 
as median  ±  interquartile range (IQR). Statistical analyses 
were performed using a nonparametric Kruskal‐Wallis test 
followed by Dunn's multiple comparison. Differences were 
considered significant at P  <  .05. GraphPad Prism 7.0b 
(GraphPad Software, Inc) was used for significance tests and 
generating plots.
2.6 | Ethics
The study had been approved by the institutional review board 
of the University Hospital of Regensburg (# 14‐160‐0029).
3 |  RESULTS
3.1 | Immune cell populations in normal 
thyroid tissue
Initially, normal thyroid tissue was stained for several im-
mune cell populations by immunohistochemistry. As shown 
in Figure 1, using specific antibodies for different immune 
cell markers normal thyroid tissue showed a low number of T 
cells (CD3 pos., 3 ± 4.1 per HPF), macrophages (CD68 pos., 
2.06 ± 1.8 per HPF), and B cells (CD20 pos., 0.33 ± 0.8 per 
HPF).
3.2 | Lymphocyte infiltration and 
thyroid cancer
Then, different thyroid carcinomas were stained for cells of 
the immune system (Figure 1). As summarized in Figure 2, 
ATC specimens showed a significantly higher number of 
CD3 (36, IQR 19.5‐67.25) and CD68 (37, 18.5‐54.5)‐posi-
tive cells in comparison to FTCs (CD3: 4; 2‐9.5, P = .0009; 
CD68: 1, 0‐3, P  =  .005), PTCs (CD3: 19, 3‐52.5, n.s.; 
CD68: 20.5, 11.75‐27.25, n.s.) and MTCs (CD3: 0, 0‐2.25, 
P  =  .0009; CD68: 6, 2.25‐10.5, n.s.), as well as normal 
thyroid tissue (CD3: P < .0001; CD68: P < .0001). In ad-
dition, cells expressing CD20, a B cell marker, could be de-
tected significantly more frequently in ATCs (2.5, 0‐6) than 
in normal thyroid tissue (P =  .005) but the differences to 
FTCs, PTCs, and MTCs were not significant. Interestingly, 
FTCs revealed similar numbers of CD3‐positive cells when 
compared to normal thyroid tissue, but less than PTCs 
(Figure 2).
F I G U R E  1  Examples of CD3 immunohistochemistry are 
shown for normal thyroid tissue (A), ATC with numerous positive 
lymphocytes (B) and FTC with only one positive lymphocyte (C)
A
B
C
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3.3 | CD1d expression on thyroid tissue
NKT cells could not be detected in thyroid tissue, most likely 
due to the fact that to our knowledge it has not yet been 
possible to stain these specific cells by immunohistochem-
istry. Nevertheless, the expression of the NKT cell activat-
ing receptor CD1d.19,20 was analyzed and as expected, there 
were more immune cells expressing CD1d in ATCs (Figure 
3). Furthermore, for the first time CD1d could be detected 
in thyroid tissue. Staining of normal thyroid tissue revealed 
membranous expression of CD1d (Figure 4) as it has been 
already shown for hematopoiesis‐derived and intestinal epi-
thelial cells.17,18,21
3.4 | CD1d expression and thyroid cancer
Additionally, different thyroid carcinomas were stained for 
CD1d expression (Figure 4). Interestingly, ATC was asso-
ciated with a significantly higher number of CD1d‐positive 
cells compared to other tumor entities and normal thyroid 
F I G U R E  2  Mean number of positive 
cells per HPF for CD3 (A), CD20 (B) and 
CD68 (C) in ATC, FTC, MTC, PTC, and 
normal thyroid tissue
F I G U R E  3  A, Mean number of 
positive immune cells per HPF for CD1d 
and (B) CD1d mRNA (Score 0‐3) in ATC, 
FTC, MTC, PTC, and normal thyroid tissue
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tissue. Additionally, looking at the respective staining pattern 
for CD1d in individual tumor cells, different characteristic 
features with regard to the localization of CD1d expression 
either in the cytoplasm or on the cell membrane could be 
found (Figure 5A). In the control group of 17 normal thy-
roid tissue samples, all showed a membranous staining pat-
tern for CD1d expression (m > c 17/17). However, ATC cells 
showed a very strong and predominantly cytoplasmatic stain-
ing of CD1d expression (12/18 cases with c > m, 4/18 with 
m > c, 2 with c = m). FTC cells stained almost completely 
negative (12/17 neg.), with only five cases of either predomi-
nantly membranous (3/17) or cytoplasmic staining (2/17). 
MTC cells were mostly stained homogeneous membranous 
and cytoplasmic (3/4 with c = m), only one case was negative 
for CD1d. PTC cells showed a similar staining as normal thy-
roid tissue with a predominantly membranous staining (22/27 
with m = c) and even partial nuclear staining (1/27), as well 
as two completely negative stainings (2/27).
3.5 | CD1d mRNA expression in various 
thyroid cancer types
CD1d transcripts were detected by chromogenic alka-
line phosphates‐based in situ hybridization in FFPE tissue 
(RNAscope). All study section showed very good mRNA 
quality, indicated by very high abundant signal (mRNA 
score >3) for the positive control ubiquitin (Figure 6A), and 
further high assay quality was revealed by no unspecific sig-
nal (mRNA score = 0) for the negative control DapB (Figure 
6B). Figure 6 shows representative areas of CD1d mRNA 
expression in ATC, FTC, MTC, PTC, and normal thyroid 
tissue. CD1d was almost exclusively expressed, at relatively 
high levels, in ATC; the lowest CD1d mRNA expression 
was seen in normal thyroid tissue (Figure 3B), consistent 
with our IHC data (Figure 4). CD1d mRNA expression in 
ATC was significantly higher than that in FTC (P  =  .02) 
and normal thyroid tissue (P < .0001; Figure 3B). FTC and 
MTC showed only sporadic CD1d mRNA expression levels 
F I G U R E  4  Different staining 
patterns for CD1d immunohistochemistry 
with predominantly cytoplasmic staining 
in ATC (A), predominantly membranous 
staining in PTC (B), equally membranous 
and cytoplasmic staining in SRC (C) or no 
staining in FTC (D)
A B
C D
F I G U R E  5  Staining patterns of normal thyroid tissue and 
different thyroid cancer types (ATC: anaplastic thyroid carcinoma; 
FTC: follicular thyroid carcinoma; MTC: medullary thyroid 
carcinoma; PTC: papillary thyroid carcinoma) (A) as well as other 
malignant tumors (SRC: sarcoma; MM: malignant melanoma; SLC: 
spindle‐cell lung cancer) (B). Staining patterns are indicated as 
predominantly membranous (m > c), predominantly cytoplasmic 
(c > m), equally membranous and cytoplasmic (c = m), negative (neg.) 
and nuclear (n)
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(Figure 3B). In contrast to FTC and MTC, PTC showed a 
moderately increased CD1d mRNA expression, signifi-
cantly higher than that in normal thyroid tissue (P = .0025; 
Figure 3B).
3.6 | CD1d expression as a diagnostic tool
Since CD1d expression was very strong and localized 
predominantly cytoplasmic in ATC cells, we next wanted 
to assess if this could be used as histopathological tool to 
help in the differential diagnosis of ATC and other medi-
astinal tumors. Therefore, specimens of sarcoma (SRC), 
MM, and SLC were examined for their respective stain-
ing profiles (Figure 7). SRC cells were either negative 
(6/11) or showed a predominantly membranous staining 
pattern (5/11), while MM cells showed a heterogeneous 
profile with all patterns present (3/7 with m > c, 2/7 with 
c > m, 2/7 neg.). All three SLC cases showed a predomi-
nantly cytoplasmic staining pattern (3/3) (Figures 5B and 
6).
F I G U R E  6  Expression of UBC (positive control) and DapB (negative control) with red chromogenic ISH (RNAscope) in a representative 
ATC (A and B) and normal thyroid tissue (C and D). Different levels of CD1d mRNA detected with red chromogenic ISH (RNAscope) in PTC 
(ACD mRNA score 1) (E) and several ATC (ACD mRNA score 1, 2 and 3) (F, G and H). All images at 4× magnification
A
B
C
D
E
F
G
H
F I G U R E  7  CD1d‐positive staining in 
ATC (A) compared to negative staining in 
MM (B) and weak membranous staining in 
SRC (C)
A B
C
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4 |  DISCUSSION
In this study, for the first time CD1d receptor expres-
sion could be detected on thyroid tissue. So far, expres-
sion of CD1d was described only on hematopoietic and 
epithelial cells of the intestine.9,17,18 Furthermore, analy-
sis of different thyroid tumor entities revealed significant 
higher expression of CD1d and CD1d mRNA in ATCs 
compared to normal thyroid tissue and all other thyroid 
tumor types. On average, patients with ATCs survive 
only a few months after primary diagnosis.22 Although ra-
diotherapy and different chemotherapies result in slightly 
improved survival rates,23,24 outcome is still very poor.22 
Therefore, several treatment strategies are currently under 
research.22 Regarding cancer therapy, in the last few years 
a lot of effort was put into the research of immunotherapy 
with NKT cells, for which CD1d serves as target recep-
tor.11,25-27 Activation pathways of NKT cells in cancer, 
CD1d mechanism, and even CD1d escape strategies in tu-
mors are topics of current studies.28 In this regard, a CD1d‐
binding glycolipid for specific stimulation of iNKT cells 
has been developed for the treatment of breast cancer.29 
Interestingly, CD1d expression in ATCs was not located 
on the cell surface but rather in the cytoplasm of the tumor 
cell. It has already been shown that CD1d expression is 
decreased in several diseases. Virus infection inhibits NKT 
cell‐CD1d function among others through downregulation 
of CD1d.30,31 In this context, herpes simplex virus 1 phos-
phorylates the type II kinesin motor protein KIF3A which 
lead to the suppression of CD1d.32 Otherwise, in systemic 
lupus erythematosus TLR9‐induced microRNA‐155 and 
Ets‐1 decrease membrane CD1d levels.33 But also in ma-
lignancies CD1d degradation could be observed. In chronic 
myeloid leukemia, activation of the Rho‐associated protein 
kinase (ROCK) mediates the reduction of membrane ex-
pression of CD1d but not the reduction of intracytoplas-
matic levels or mRNA transcripts34 and a certain kind of 
invasive breast cancer is also associated with downregu-
lated CD1d.35 Regarding the CD1d receptor molecule, a 
Thr/Ser residue motif in the cytoplasmatic tail seems to be 
pivotal for the surface expression.36 Nevertheless, future 
research has to focus on the mechanism of CD1d down-
regulation, especially in ATCs. Although CD1d downregu-
lation seems to represent dedifferentiation, a correlation 
between cytoplasmatic, respectively membranous expres-
sion and survival time could not be found; this is may be 
due to the limited number of patients.
Infiltrating lymphocytes and their function related to dif-
ferent pathologies are subject to ongoing research. Concerning 
the thyroid gland, lymphocytes are mainly analyzed in Grave's 
disease and Hashimoto's thyroiditis due to the autoimmune 
background.37 These data were compared to lymphocyte in-
filtration into thyroidal malignant tumors, mainly focused on 
the immunoregulatory potential.37-39 Although previously 
published data revealed no increase of lymphocytes in ATCs 
compared to other thyroid carcinomas,40,41 Lindhorst et al42 
showed clear evidence that lymphocyte infiltration is more 
frequent in ATCs, which can be confirmed by results of the 
present study. Interestingly, in ATC patients, myeloid‐derived 
suppressor cells are increased in the peripheral blood and 
cell‐mediated immune responses seem to be suppressed.43 
Furthermore, in ATCs, increased secretion of CXCL10 has 
been reported.44 In turn, CXCL10 binds to CXCR3 subse-
quently leading to T and NKT cell activation.45,46 In addition 
to its function in coordinating inflammation and immune re-
sponse, it has been already shown that CXCR3 and its ligand 
CXCL10 are involved in the progression of several different 
cancer types.47-52 However, further research will be required 
to evaluate if immunotherapy can be an option for ATCs in 
the future and to prove if CD1d represents an appropriate tar-
get for such treatment.
An interesting finding in our study is the possibility to use 
CD1d immunohistochemistry in an extended panel for the 
differential diagnosis of mediastinal lesions in a difficult clin-
icopathologic setting. Due to its location near the upper me-
diastinum and often advanced stage with infiltration of other 
organs and structures in the vicinity, it can be difficult to dis-
tinguish ATC from other malignant neoplasms in the mediasti-
nal area or metastases, such as poorly differentiated squamous 
carcinoma (SCC) of the head and neck,53 sarcoma (SRC),54,55 
malignant melanoma (MM),56 sarcomatoid mesothelioma or 
lung cancer.57 In some cases, diagnosis will be possible upon 
histopathologic examination alone, while other cases require 
additional immunohistochemical analysis. Aside from poorly 
differentiated SCC with positive epithelial markers, the dis-
tinction between SRC, MM, and ATC can be a problem when 
other specific markers, for example HMB45 or Melan A, are 
also negative. Additionally, vimentin has been reported to be 
positive in a number of ATC.58,59 A strong, predominantly 
cytoplasmic positivity for CD1d seems very characteristic 
for ATC, while other poorly differentiated neoplasms that 
can occur in the mediastinum, for example undifferentiated 
sarcomas or metastases of malignant melanoma, show either 
negative staining for CD1d or a predominantly membranous 
pattern. We therefore suggest adding the immunohistochem-
ical staining for CD1d to a wider panel of different cytokera-
tins, melanocytic markers, thyroid markers (such as TTF‐1 and 
PAX8) and lymphocytic antigens to help establishing the di-
agnosis of ATC. Further, our findings should be confirmed in 
immunohistochemical studies with larger numbers of ATC.60
The scope of our study is certainly limited by the small 
amount of cases that were included. For further investigations 
regarding the significance of different levels and locations of 
CD1d expression, a larger number of ATC cases needs to be 
surveyed. Also, in this study the correlation between CD1d 
expression on different thyroid malignancies and its possible 
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prognostic and therapeutic impact was not investigated. This 
should be addressed in further studies.
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